NEUROCRINE BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.2 USD | +0.09% |
|
-2.80% | +5.51% |
Presenter SpeechMarc Goodman (Analysts)All right. Good afternoon, everybody. Thanks for joinin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinsonâs disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinsonâs disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
Calendar
2024-05-14
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
139
USD
Average target price
157.8
USD
Spread / Average Target
+13.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.51% | 13.99B | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +2.10% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Transcript : Neurocrine Biosciences, Inc. Presents at SVB Securities Global Biopharma Conference, Feb-14-2023 12